Paleoclimatic reconstruction during the Little Ice Age in the Llanganuco basin, Cordillera Blanca (Peru)

The Equilibrium Line Altitude (ELA, m) is a good indicator for the impact of climate change on tropical glaciers , because it varies in time and space depending on changes in temperature and/or precipitation.The estimation of the ELA and paleoELA using the Area x Altitude Balance Ratio method (AABR; Osmaston, 2005) requires knowing the surface and hypsometry of glaciers or paleoglaciers (Benn et al. 2005) and the Balance Ratio (BR) correct (Rea, 2009). In the Llanganuco basin (~ 9°3´S; 77°37´W) there are very well preserved moraines near the current glaciers front. These deposits provide information to reconstruct the extent of paleoglaciers since the Little Ice Age (LIA) and deduce some paleo-climatic variables. The goal of this work has been to reconstruct the paleotemperature (°C) during LIA, deduced from the difference between ELA AABR2016 and paleoELA AABRLIA. The paleoclimatic reconstruction was carried out in 6 phases: Phase 1) Development of a detailed geomorphological map (scale 1/10,000), in order to identify glacial landforms (advance moraines and polished rocks) which, due to their geomorphological context, can be considered of LIA, so palaeoglaciers can be delimited. Current glacial extension was done using dry season, high resolution satellite images. Phase 2) Glacial bedrock Reconstruction from glacier surface following the GLABTOP methodology (Linsbauer et al 2009). Phase 3) 3D reconstruction of paleoglacial surface using GLARE tool, based on bed topography and flow lines for each defined paleoglacial (Pellitero et al., 2016). As perfect plasticity model does not reflect the tension generated by the side walls of the valley, form factors were calculated based on the glacier thickness, lateral moraines and the geometry of the valley following the equation proposed by Nye (1952), adjusting the thicknesses generated in the paleoglacial front. Phase 4) Calculation of BR in a reference glacier (Artesonraju; 8° 56’S; 77º38’W), near to the study area, using the product BR = b • z • s, where BR= Balance Ratio; b= mass balance measured in fieldwork 2004-2014 (m); z= average altitude (meters) and s= surface (m2) of each altitude band of the glacier (with intervals of 100 m altitude). A value BR = 2.3 was estimated. Phase 5) Automatic reconstruction of the ELA AABR2016 and paleoELA AABRLIA using ELA Calculation tool (Pellitero et al. 2015) after 3D reconstruction of the glacial and paleoglacial surface in phases 2 and 3. Phase 6) Estimation of paleotemperature during LIA by solving the equation of Porter et al. (1995): ∆T (°C)= ∆ELA • ATLR, where ∆T= air temperature depression (ºC); ∆ELA = variation of ELA AABR 2016-LIA and ATLR = Air Temperature Lapse Rate, using the average global value of the Earth (0.0065 °C/m), considered valid for tropics. The results obtained were: ELA AABR2016= 5260m, paleoELA AABRLIA= 5084m, and ∆T = 1.1 °C. The reconstruction of air paleotemperature is consistent with different studies that have estimated values between 1–2 °C colder than the present, with intense rainfall (Matthews & Briffa, 2005; Malone et al., 2015)

Randomized crossover pharmacokinetic evaluation of subcutaneous versus intravenous granisetron in cancer patients treated with platinum-based chemotherapy

BACKGROUND: 5-HT3-receptor antagonists are one of the mainstays of antiemetic treatment, and they are administered either i.v. or orally. Nevertheless, sometimes neither administration route is feasible, such as in patients unable to admit oral intake managed in an outpatient setting. Our objective was to evaluate the bioavailability of s.c. granisetron. PATIENTS AND METHODS: Patients receiving platinum-based chemotherapy were randomized to receive 3 mg of granisetron either s.c. or i.v. in a crossover manner during two cycles. Blood and urine samples were collected after each cycle. Pharmacokinetic parameters observed with each administration route were compared by analysis of variance. RESULTS: From May to November 2005, 31 patients were included and 25 were evaluable. Subcutaneous granisetron resulted in a 27% higher area under the concentration-time curve for 0-12 hours (AUC(0-12h)) and higher levels at 12 hours, with similar values for AUC(0-24h). The maximum concentration was lower with the s.c. than with the i.v. route and was observed 30 minutes following s.c. administration. CONCLUSION: Granisetron administered s.c. achieves complete bioavailability. This is the first study that shows that s.c. granisetron might be a valid alternative to i.v. delivery. Further trials to confirm clinical equivalence are warranted. This new route of administration might be especially relevant for outpatient management of emesis in cancer patients

Randomized pharmacokinetic study comparing subcutaneous and intravenous palonosetron in cancer patients treated with platinum based chemotherapy

BACKGROUND: Palonosetron is a potent second generation 5- hydroxytryptamine-3 selective antagonist which can be administered by either intravenous (IV) or oral routes, but subcutaneous (SC) administration of palonosetron has never been studied, even though it could have useful clinical applications. In this study, we evaluate the bioavailability of SC palonosetron. PATIENTS AND METHODS: Patients treated with platinum-based chemotherapy were randomized to receive SC or IV palonosetron, followed by the alternative route in a crossover manner, during the first two cycles of chemotherapy. Blood samples were collected at baseline and 10, 15, 30, 45, 60, 90 minutes and 2, 3, 4, 6, 8, 12 and 24 h after palonosetron administration. Urine was collected during 12 hours following palonosetron. We compared pharmacokinetic parameters including AUC0-24h, t1/2, and Cmax observed with each route of administration by analysis of variance (ANOVA). RESULTS: From October 2009 to July 2010, 25 evaluable patients were included. AUC0-24h for IV and SC palonosetron were respectively 14.1 and 12.7 ng × h/ml (p = 0.160). Bioavalability of SC palonosetron was 118% (95% IC: 69-168). Cmax was lower with SC than with IV route and was reached 15 minutes following SC administration. CONCLUSIONS: Palonosetron bioavailability was similar when administered by either SC or IV route. This new route of administration might be specially useful for outpatient management of emesis and for administration of oral chemotherapy

Proceso asistencial integrado de esclerosis lateral amiotrófica

O proceso asistencial integrado da esclerose lateral amiotrófica, elaborouse co obxectivo de crear un proceso de traballo común en todas as áreas para facilitar a asistencia sanitaria ás persoas diagnosticadas desta enfermidade. Establécense actuacións como o asesoramento continuo, as consultas en acto único, a coordinación asistencial, tanto entre especialidades como coa atención primaria e a coordinación administrativa do sistema socio sanitario. Neste proceso participaron profesionais das diferentes áreas sanitarias especialistas en neuroloxía, endocrinoloxía, neumoloxía, psicoloxía clínica, rehabilitación, traballo social e hospitalización a domicilioEl proceso asistencial integrado de la esclerosis lateral amiotrófica, se elaboró con el objetivo de crear un proceso de trabajo común en todas las áreas para facilitar la asistencia sanitaria a las personas diagnosticadas de esta enfermedad. Se establecen actuaciones como el asesoramiento continuo, las consultas en acto único, la coordinación asistencial, tanto entre especialidades como con la atención primaria y la coordinación administrativa del sistema socio sanitario. En este proceso participaron profesionales de las diferentes áreas sanitarias especialistas en neurología, endocrinología, neumología, psicología clínica, rehabilitación, trabajo social y hospitalización a domicili

Viral RNA load in plasma is associated with critical illness and a dysregulated host response in COVID‑19

Background. COVID-19 can course with respiratory and extrapulmonary disease. SARS-CoV-2 RNA is detected in respiratory samples but also in blood, stool and urine. Severe COVID-19 is characterized by a dysregulated host response to this virus. We studied whether viral RNAemia or viral RNA load in plasma is associated with severe COVID-19 and also to this dysregulated response. Methods. A total of 250 patients with COVID-19 were recruited (50 outpatients, 100 hospitalized ward patients and 100 critically ill). Viral RNA detection and quantification in plasma was performed using droplet digital PCR, targeting the N1 and N2 regions of the SARS-CoV-2 nucleoprotein gene. The association between SARS-CoV-2 RNAemia and viral RNA load in plasma with severity was evaluated by multivariate logistic regression. Correlations between viral RNA load and biomarkers evidencing dysregulation of host response were evaluated by calculating the Spearman correlation coefficients. Results. The frequency of viral RNAemia was higher in the critically ill patients (78%) compared to ward patients (27%) and outpatients (2%) (p < 0.001). Critical patients had higher viral RNA loads in plasma than non-critically ill patients, with non-survivors showing the highest values. When outpatients and ward patients were compared, viral RNAemia did not show significant associations in the multivariate analysis. In contrast, when ward patients were compared with ICU patients, both viral RNAemia and viral RNA load in plasma were associated with critical illness (OR [CI 95%], p): RNAemia (3.92 [1.183–12.968], 0.025), viral RNA load (N1) (1.962 [1.244–3.096], 0.004); viral RNA load (N2) (2.229 [1.382–3.595], 0.001). Viral RNA load in plasma correlated with higher levels of chemokines (CXCL10, CCL2), biomarkers indicative of a systemic inflammatory response (IL-6, CRP, ferritin), activation of NK cells (IL-15), endothelial dysfunction (VCAM-1, angiopoietin-2, ICAM-1), coagulation activation (D-Dimer and INR), tissue damage (LDH, GPT), neutrophil response (neutrophils counts, myeloperoxidase, GM-CSF) and immunodepression (PD-L1, IL-10, lymphopenia and monocytopenia). Conclusions. SARS-CoV-2 RNAemia and viral RNA load in plasma are associated with critical illness in COVID-19. Viral RNA load in plasma correlates with key signatures of dysregulated host responses, suggesting a major role of uncontrolled viral replication in the pathogenesis of this disease.This work was supported by awards from the Canadian Institutes of Health Research, the Canadian 2019 Novel Coronavirus (COVID-19) Rapid Research Funding initiative (CIHR OV2 – 170357), Research Nova Scotia (DJK), Atlantic Genome/Genome Canada (DJK), Li-Ka Shing Foundation (DJK), Dalhousie Medical Research Foundation (DJK), the “Subvenciones de concesión directa para proyectos y programas de investigación del virus SARS‐CoV2, causante del COVID‐19”, FONDO–COVID19, Instituto de Salud Carlos III (COV20/00110, CIBERES, 06/06/0028), (AT) and fnally by the “Convocatoria extraordinaria y urgente de la Gerencia Regional de Salud de Castilla y León, para la fnanciación de proyectos de investigación en enfermedad COVID-19” (GRS COVID 53/A/20) (CA). DJK is a recipient of the Canada Research Chair in Translational Vaccinology and Infammation. APT was funded by the Sara Borrell Research Grant CD018/0123 funded by Instituto de Salud Carlos III and co-fnanced by the European Development Regional Fund (A Way to Achieve Europe programme). The funding sources did not play any role neither in the design of the study and collection, not in the analysis, in the interpretation of data or in writing the manuscript

Clonal chromosomal mosaicism and loss of chromosome Y in elderly men increase vulnerability for SARS-CoV-2

The pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID-19) had an estimated overall case fatality ratio of 1.38% (pre-vaccination), being 53% higher in males and increasing exponentially with age. Among 9578 individuals diagnosed with COVID-19 in the SCOURGE study, we found 133 cases (1.42%) with detectable clonal mosaicism for chromosome alterations (mCA) and 226 males (5.08%) with acquired loss of chromosome Y (LOY). Individuals with clonal mosaic events (mCA and/or LOY) showed a 54% increase in the risk of COVID-19 lethality. LOY is associated with transcriptomic biomarkers of immune dysfunction, pro-coagulation activity and cardiovascular risk. Interferon-induced genes involved in the initial immune response to SARS-CoV-2 are also down-regulated in LOY. Thus, mCA and LOY underlie at least part of the sex-biased severity and mortality of COVID-19 in aging patients. Given its potential therapeutic and prognostic relevance, evaluation of clonal mosaicism should be implemented as biomarker of COVID-19 severity in elderly people. Among 9578 individuals diagnosed with COVID-19 in the SCOURGE study, individuals with clonal mosaic events (clonal mosaicism for chromosome alterations and/or loss of chromosome Y) showed an increased risk of COVID-19 lethality

Evaluation of sanitary technology: dressings based on humid environment cure for chronic wounds

El bombardeo constante en producción, diferenciación e idoneidad de tipos de apósitos al que se ha sometido en las dos últimas décadas el mundo de las heridas por parte de la industria hace necesario y obligatorio por parte del personal de la salud un conocimiento exhaustivo de la tecnología que tiene en sus manos. Los informes de Tecnología Sanitaria se han convertido en una buena herramienta para cubrir tanto la evaluación de los apósitos basados en cura en ambiente húmedo, como la precisión de sus indicaciones. En el presente trabajo analizamos la estructura de un Informe de Evaluación de Tecnología Sanitaria desde su marco general hasta su particularidad en el campo de los apósitos para el cuidado de heridas, las características básicas y estándar solicitadas por el profesional y el enfermo, manteniendo en todo momento unas visión integral desde el cuidado enfermero. Proponemos, al final, un informe ideal para hospital o centro de salud imaginario, que se ajuste a todas las premisas de calidad, las realidades de cada ámbito de salud y las posibilidades de cada sistema sanitario.In the last two decades the wounds sector has been subjected by the industry to a constant shelling in production, differentiation and suitability of types of dressings that requires necessarily and by imperative from the health staff an exhaustive knowledge of the technology that they have in their hands. The Sanitary Technology reports have become a good tool for covering both the evaluation of the dressings based on humid environment cure and their indications precision. In the present work we analyze the structure of a Sanitary Technology Evaluation report, from its general context to its special features in the field of dressings for wounds care, and the basic and standard characteristics requested by professionals and patients, always keeping an integral vision from the nurse care perspective. Finally, we propose an ideal report for a fictitious hospital or health center, that adapts itself to all the premises of quality, the realities of every health field and the possibilities of each sanitary system

Resultados en línea de un aprendizaje basado en proyectos en las materias de física

Se presenta parte de los resultados de un Proyecto de Innovación Educativa de la Universidad de Vigo (2011-2013), en donde el material visible surge de la resolución de un desafío experimental en las materias de Física de primer curso de diferentes grados en ingeniería empleando una metodología de Aprendizaje Basado en Proyectos

Randomized pharmacokinetic study comparing subcutaneous and intravenous palonosetron in cancer patients treated with platinum based chemotherapy

BACKGROUND: Palonosetron is a potent second generation 5- hydroxytryptamine-3 selective antagonist which can be administered by either intravenous (IV) or oral routes, but subcutaneous (SC) administration of palonosetron has never been studied, even though it could have useful clinical applications. In this study, we evaluate the bioavailability of SC palonosetron. PATIENTS AND METHODS: Patients treated with platinum-based chemotherapy were randomized to receive SC or IV palonosetron, followed by the alternative route in a crossover manner, during the first two cycles of chemotherapy. Blood samples were collected at baseline and 10, 15, 30, 45, 60, 90 minutes and 2, 3, 4, 6, 8, 12 and 24 h after palonosetron administration. Urine was collected during 12 hours following palonosetron. We compared pharmacokinetic parameters including AUC0-24h, t1/2, and Cmax observed with each route of administration by analysis of variance (ANOVA). RESULTS: From October 2009 to July 2010, 25 evaluable patients were included. AUC0-24h for IV and SC palonosetron were respectively 14.1 and 12.7 ng × h/ml (p = 0.160). Bioavalability of SC palonosetron was 118% (95% IC: 69-168). Cmax was lower with SC than with IV route and was reached 15 minutes following SC administration. CONCLUSIONS: Palonosetron bioavailability was similar when administered by either SC or IV route. This new route of administration might be specially useful for outpatient management of emesis and for administration of oral chemotherapy